Kinase activity of mutant LRRK2 mediates neuronal toxicity

被引：510

作者：

Smith, Wanli W.

Pei, Zhong

Jiang, Haibing

Dawson, Valina L.

Dawson, Ted M.

Ross, Christopher A.

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21287 USA

[2] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA

[3] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA

[4] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21287 USA

[5] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21287 USA

[6] Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD 21287 USA

来源：

NATURE NEUROSCIENCE | 2006年 / 9卷 / 10期

关键词：

D O I：

10.1038/nn1776

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Mutations in the the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal- dominant Parkinson disease and some cases of sporadic Parkinson disease. Here we found that LRRK2 kinase activity was regulated by GTP via the intrinsic GTPase Roc domain, and alterations of LRRK2 protein that reduced kinase activity of mutant LRRK2 correspondingly reduced neuronal toxicity. These data elucidate the pathogenesis of LRRK2-linked Parkinson disease, potentially illuminate mechanisms of sporadic Parkinson disease and suggest therapeutic targets.

引用

页码：1231 / 1233

页数：3

共 50 条

[21] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
T. De Wit
V. Baekelandt
E. Lobbestael
Molecular Neurobiology, 2019, 56 : 5273 - 5286
[22] Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo
Kozina, Elena
Sadasivan, Shankar
Jiao, Yun
Dou, Yuchen
Ma, Zhijun
Tan, Haiyan
Kodali, Kiran
Shaw, Timothy
Peng, Junmin
Smeyne, Richard J.
BRAIN, 2018, 141 : 1753 - 1769
[23] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
De Wit, T.
Baekelandt, V.
Lobbestael, E.
MOLECULAR NEUROBIOLOGY, 2019, 56 (08) : 5273 - 5286
[24] Triazolopyridazine LRRK2 kinase inhibitors
Franzini, Maurizio
Ye, Xiaocong M.
Adler, Marc
Aubele, Danielle L.
Garofalo, Albert W.
Gauby, Shawn
Goldbach, Erich
Probst, Gary D.
Quinn, Kevin P.
Santiago, Pam
Sham, Hing L.
Tam, Danny
Anh Truong
Ren, Zhao
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (07) : 1967 - 1973
[25] RedOx regulation of LRRK2 kinase activity by active site cysteines
Trilling, Chiara R.
Weng, Jui-Hung
Sharma, Pallavi Kaila
Nolte, Viktoria
Wu, Jian
Ma, Wen
Boassa, Daniela
Taylor, Susan S.
Herberg, Friedrich W.
NPJ PARKINSONS DISEASE, 2024, 10 (01)
[26] RedOx regulation of LRRK2 kinase activity by active site cysteines
Chiara R. Trilling
Jui-Hung Weng
Pallavi Kaila Sharma
Viktoria Nolte
Jian Wu
Wen Ma
Daniela Boassa
Susan S. Taylor
Friedrich W. Herberg
npj Parkinson's Disease, 10
[27] Inhibition of LRRK2 Kinase Activity in the Treatment of Crohn's Disease
Deloer, Sharmina
Fuss, Ivan
Suebsuwong, Chalada
Kumar, Kunal
Devita, Robert J.
Peter, Inga
Strober, Warren
JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
[28] LRRK2 kinase activity is necessary for development and regeneration in Nematostella vectensis
Holmes, Grace
Ferguson, Sophie R.
Lewis, Patrick Alfryn
Echeverri, Karen
NEURAL DEVELOPMENT, 2024, 19 (01)
[29] Novel cinnoline-based inhibitors of LRRK2 kinase activity
Garofalo, Albert W.
Adler, Marc
Aubele, Danielle L.
Bowers, Simeon
Franzini, Maurizio
Goldbach, Erich
Lorentzen, Colin
Neitz, R. Jeffrey
Probst, Gary D.
Quinn, Kevin P.
Santiago, Pam
Sham, Hing L.
Tam, Danny
Truong, Anh P.
Ye, Xiaocong M.
Ren, Zhao
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (01) : 71 - 74
[30] Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
Lobbestael, E.
Civiero, L.
De Wit, T.
Taymans, J. -M.
Greggio, E.
Baekelandt, V.
SCIENTIFIC REPORTS, 2016, 6

← 1 2 3 4 5 →